Format

Send to

Choose Destination
Nat Rev Cancer. 2009 May;9(5):321-6. doi: 10.1038/nrc2615. Epub 2009 Apr 3.

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.

Author information

1
The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Victoria, Australia. msc@soton.ac.uk

Abstract

Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.

PMID:
19343035
DOI:
10.1038/nrc2615
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center